221 results about "Caplet Dosage Form" patented technology

There is provided a pharmaceutical composition comprising eplerenone in solid particulate form, wherein at least 90% of the eplerenone particles are smaller than about 15 .mu.m, for example about 0.01 .mu.m to about 1 .mu.m, in diameter. The composition can be adapted for oral administration, for example as a tablet or capsule comprising eplerenone in a unit dosage amount of about 10 mg to about 1000 mg and one or more excipients.

Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process that includes (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of paclitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the paclitaxel solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. In a preferred embodiment, microparticles of the porous paclitaxel matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

The invention relates to a novel dispersible tablet which is prepared from a certain amount of antipsychotic medicines or pharmaceutically acceptable salt or ester thereof or mixture thereof, a certain amount of selective serotonin reuptake inhibitors (SSRIs) and at least one of pharmaceutically acceptable carriers, wherein the antipsychotic medicines are aripiprazole, fluvoxamine, escitalopram, olanzapine, mirtazapine, clozapine, ziprasidone, mianserin, agomelatine, lurasidone, iloperidone, blonanserin, moclobemide, timiperone, palipeddone, trimipramine, carpipramine, lofepramine or mosapramine. The novel dispersible tablet is used for preventing, delaying or treating depression or schizophrenia of patients. Compared with common tablets or capsules, the novel dispersible tablet has the characteristics of quick and uniform dispersion, short disintegration time, quick medicine absorption, high bioavailability and good stability, and is convenient to take.

The invention relates to the technical field of pharmaceutical preparation, in particular to an effervescent tablet containing imatinib mesylate and a method for preparing the same. The effervescent tablet comprises 25 to 500 milligrams of the imatinib mesylate and an acid base pair which is acceptable in pharmacy; furthermore, a filling agent, an adhesive, a disintegrating agent, a lubricating agent, a sweetening agent and a flavour modifying agent which are acceptable in pharmacy can be added in the effervescent tablet. The effervescent tablet containing the imatinib mesylate has the advantages of faster action speed compared with the tablets and capsulated drugs in the market, has convenient use and good taste in taking, and is more suitable for children, the elderly, and patients who can not swallow solid medicines.

The invention relates to an oral liquid crystal sustained-released composition and a preparation method thereof. Active ingredients are distributed in glyceryl monooleate and lipid material in the composition to achieve the aim of slowly releasing the medicine. The preparation method of the pharmaceutical composition is as follows: the active ingredients, glyceryl monooleate and lipid material are prepared in a moderate method; the mixture is separately loaded in a hard capsule shell or soft capsule, and the sustained-released capsule is prepared. The content of the sustained-released capsule forms liquid crystal phase after encountering water to inhibit the release of the medicine. The pharmaceutical composition of the invention has simple preparing process, the active ingredients can be sustained-release, and the parameters influencing the release are few. Therefore, the composition of the invention is more suitable for industrial production with better safety.

The present disclosure provides improved compositions comprising rifabutin, clarithromycin, and clofazimine for use in the treatment of Inflammatory Bowel Diseases. In one instance, the compositions may comprise a formulation of rifabutin, clarithromycin, and clofazimine in a single dosage form, such as a capsule, tablet, etc., with one or more specific excipients.

The invention discloses a levocetirizine dihydrochloride granule and preparation and detection methods thereof. The specification of the levocetirizine dihydrochloride particle is 2.5 mg, and milk sugar is used as filling agent. The levocetirizine dihydrochloride granule dispenses with the process of disintegration of tablets and capsules in a human body, the degree of dispersion in the human bodyis superior to the tablets and the capsules, and the absorption is faster than the tablets, the capsules and dispersible tablets; and the flowability, the dispersibility and the adhesiveness are better than the dispersible tablets, the granule is convenient to take, the mouthfeel is easier to adjust, and the curative effect of the medicine can be guaranteed to be better played.

The invention provides a herba epimedii extract, in particular to a high-content herba epimedii total flavonoids extract, and the preparation method thereof mainly comprises the following steps: (1) alkali-ethanol-water is taken as a menstruum for refluxing extraction; (2) decompression and concentration are carried out; (3) pH value is adjusted; (4) macroporous resin column elution is carried out; and (5) an eluant is dried and the content of the obtained total flavonoids is over 65 percent and the content of icariin is over 20 percent. The extract can be prepared into various oral preparations according to the requirements in pharmacy, which can be hard capsules, soft capsules, conventional tablets, orally disintegrating tablets, buccal tablets, dispersible tablets, sustained-release preparations, controlled release preparations, granules, water-paste pills, dripping pills, honeyed pills, and the like. The extract and effective medicines containing the extract can be applied to preparing brain tissue protective agents, especially to preparing medicines that prevent and treat cerebral infarction, cerebral infarction sequela and other ischemic cerebrovascular diseases.

The invention relates to a medical composition with active components of adefovir dipivoxil and another rnucleotide (acid) anti-virus medicine and the preparation method and usage thereof. The adefovir dipivoxil and anther rnucleotide (acid) anti-virus medicine are taken as the active components, and mixed with a plurality of pharmaceutically acceptable supplements to prepare the medical composition; and the invention can be applied in treatment of viral hepatitis B. The adefovir dipivoxil and anther rnucleotide (acid) anti-virus medicine are taken as raw materials of the invention content, a plurality of supplements with special type and proportion are added, and various kinds of oral preparations such as tablet, capsule, dispersion, chewable tablet, oral disintegrating tablet, buccal tablet, dropping pill and soft capsule are prepared and developed according to the technical method described by the invention.

A tablet, pill or capsule containing a material which produces sound waves when the tablet, pill or capsule is exposed to the gastrointestinal system. A two step method for oral drug compliance monitoring. The first step is to ingest a tablet, pill or capsule containing a material which produces sound waves when the tablet, pill or capsule is exposed to the gastrointestinal system of a person. The second step is to detect the sound waves produced when the tablet, pill or capsule is exposed to the gastrointestinal system to confirm that the person has ingested the tablet, pill or capsule.

The invention discloses a composition as well as a preparation method and a preparation thereof. The composition of the present invention includes nicotinamide mononucleotide, an ion exchange resin, acoating material, and a plasticizer. The preparation method comprises the following steps: preparing the drug-loaded resin particles, and coating the drug-loaded resin particles. The coated drug-loaded resin particles are mixed with other auxiliary materials to prepare corresponding dosage forms, such as oral suspension, tablets, capsules, granules, cream, ointment, facial masks and the like. Thecomposition is simple in production process, easy to amplify and produce, capable of effectively improving the stability of nicotinamide mononucleotide, accurate in dosage, lasting in effect and stable in curative effect.

At present, the most prevalent pharmaceutical dosage forms, the oral immediate-release tablets and capsules, are granular solids. The problem of such solids is that their microstructure and properties are not predictable from physical models. As a consequence, product development and manufacture are resource-intensive and time-consuming, and quality control is statistical by testing instead of by design. Furthermore, the range of the drug release rate, and the variety of active ingredients that can be processed to a functional product, are limited in such dosage forms. Presented herein, accordingly, is a fibrous dosage form suitable for immediate-release applications prepared by a predictable liquid-based process. The fibrous dosage form includes a drug-containing solid comprising a three dimensional structural network of one or more drug-containing fibers.

The invention relates to the technical field of medicines, in particular to a colon-targeted capsule for treating ulcerative colitis and a preparation technology thereof. Capsule contents of the colon-targeted capsule are prepared from 5-10 parts of gastric-dissolved pellets and 10-20 parts of enteric-coated pellets, the gastric-dissolved pellets are prepared from rhizoma atractylodis macrocephalae volatile oil, beta-cyclodextrin, a pill accelerator and the like, the enteric-coated pellets are prepared from coptidis rhizoma, saposhnicovia divaricata, fructus mume extracts, a pill accelerator and a colon-targeted coating material. Accordingly, the colon-targeted capsule is characterized in that the symptoms and the causes are treated, bioavailability is high, different ingredients are released in the stomach and the colon, and the capsule has the advantages that oral administration is safe and convenient, the coating prescription is simple, and industrial production can be conducted. Animal experiments show that the colon-targeted capsule has the obvious therapeutic effect on the ulcerative colitis, the treatment effect of the medium dosage is close to and even superior to the positive control drug SASP, and a brand new preparation is provided for clinically treating the ulcerative colitis.

The invention relates to a gastrodine compound and a pharmaceutical composition thereof. The gastrodine compound is a crystal. The X-ray powder diffraction determines that the characteristic peaks are displayed when 2theta+/-0.2 degree is 4.5 degrees, 5.7 degrees, 7.9 degrees, 10.3 degrees, 11.2 degrees, 13.0 degrees, 16.4 degrees, 19.6 degrees, 21.2 degrees, 22.7 degrees, 24.8 degrees, 26.7 degrees, 29.6 degrees, 34.1 degrees and 35.3 degrees. The gastrodine compound has very high stability, thereby greatly enhancing the medicine safety. The invention also relates to a pharmaceutical composition preparation containing the gastrodine compound. The composition preparation can be a freeze-dried powder injection, injection, tablet or capsule. The gastrodine freeze-dried powder injection, injection, tablet or capsule preparation provided by the invention has the advantages of simple prescription technique, obviously higher stability, and enhances the medicine safety and effectiveness.

The invention discloses an acidum citricum hypoglossal tablet and the preparing method, relating to a tablet and the preparation method. The invention means to solve problems: current acidum citricum are all oral tablets and capsule, the content is large and increases liver injury, and it is easy to generate adverse effect. The comprised component and their weight proportion are as follows: acidum citricum 20 -30 units, manna sugar 45-65 units, lactin 65-105 units, sweetener 0. 5-1. 5 units, ethanol solution with concentration being 5%PVPK30 30 -40 units and dolomol 4-8 units. The preparation method comprises following steps: sifting sot material with nylon screen of 18-20 order to produce particular, drying at 55-65 Deg. C; sifting granular with screen of 14-16 order and placing for 5-7 hours for sheeting. The tablet is characterized by small content, increased biological utilization rate, low adverse effect rate, and the method is characterized by short and simple process.

The invention belongs to the field of pharmaceutical industry, and relates to moxifloxacin capsules. A content of the moxifloxacin capsules comprises moxifloxacin hydrochloride, microcrystalline cellulose, sodium carboxymethyl starch, and magnesium stearate; the ingredients above are mixed, an obtained mixture is made into particles, and the particles are packaged by gelatin capsules so as to obtain the moxifloxacin capsules. Novel prescription and novel technology adopted by a preparation method of the moxifloxacin capsules are capable of avoiding reduction of dissolubility in storage processes, and ensuring f2 equivalence of the moxifloxacin capsules in four dissolution mediums with original grinded capsules.

The invention relates to a lansoprazole compound and a pharmaceutical composition thereof. The lansoprazole compound is a crystal. The characteristic peaks measured by X-ray powder diffraction are shown as 3.6, 4.8, 10.9, 14.0, 15.4, 16.9, 22.6, 24.7, 28.5, 32.1, 35.2, 36.7 and 39.3 at 2theta+/-0.2 degrees. The medical composition preparation comprises the lansoprazole compound. The preparation is in form of freeze-dried powder injections, troches, capsules, enteric-coated tablets or enteric-coated capsules. The lansoprazole compound prepared by the invention has better solubleness and stability. The lansoprazole pharmaceutical composition prepared by using the lansoprazole compound provided by the invention as the effective component is good in stability.

The invention relates to a composite slow-release agent, wherein it contains indomethacin, aminoglucose salt, slow-release material and other findings, while their ratios are 5-45%, 20-80%, 1-75%, and the left is findings. Its preparation comprises that mixing indomethacin and/or aminoglucose salt, and slow-release material and/or packs, then adding other findings, using general slow-release technique to obtain one or several skeleton or mould-contoro slow-release agent. The invention can be made into particle, oral, tablet or capsule. The invention can keep stable blood drug density in 8-36h, reduce side effect.

Disclosed is a solid dispersion and a preparation method therefor. The solid dispersion contains a glucokinase activator, an isotopic label thereof, or a medicinal salt thereof and a polymer support. Further disclosed is a solid dispersion composition containing the solid dispersion and an excipient. Also disclosed is an oral preparation of the glucokinase activator, containing the solid dispersion or the solid dispersion composition. Also disclosed is a tablet and a capsule of the glucokinase activator and a preparation method therefor. In addition, also disclosed is the uses of the solid dispersion, the solid dispersion composition and the oral preparations comprising the tablet and the capsule, which can be used for treating and/or preventing selected diseases or medical conditions and especially one or more diseases selected from type I diabetes mellitus, type II diabetes mellitus, impaired glucose tolerance, impaired fasting glucose and hyperglycemia.

The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules.